IngentaConnect Treatment Options for Merkel Cell Carcinoma

Authors: Beenken S.W.¹; Urist M.M.¹

Source: Journal of the National Comprehensive Cancer Network (JNCCN), Volume 2, Number 1, 1 January 2004 , pp. 89-92(4)

Publisher: Jones and Bartlett Publishers

Abstract:

Merkel cell carcinoma (MCC) or neuroendocrine carcinoma of the skin is uncommon, often aggressive, and has a poor prognosis. Complete surgical excision with histologic documentation of clear resection margins is recommended for the primary cancer. Retrospective analysis of clinical data strongly suggests that adjuvant radiotherapy improves local control of MCC, but no evidence has been published that it prolongs survival. Sentinel lymph node biopsy is a useful method of determining the need for regional lymph node dissection in stage I patients. Chemotherapy regimens similar to those employed for small cell carcinoma of the lung have been recommended for advanced MCC. Patients often show an initial response to therapy, but it is usually short-lived. The three-year overall survival for patients with MCC is 31%. Before an improvement in long-term survival can be realized, early detection, appropriate use of surgery and radiation therapy, and the development of effective systemic chemotherapy are required.

Keywords: MERKEL CELL CARCINOMA; NEUROENDOCRINE CARCINOMA OF THE SKIN; SENTINEL LYMPH NODE BIOPSY; ADJUVANT RADIATION THERAPY; ADJUVANT CHEMOTHERAPY

Document Type: Research article

Affiliations: 1: Department of Surgery, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama.

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$20.00 plus tax